Programme Book
Total Page:16
File Type:pdf, Size:1020Kb
EAU 16-20 April 2010 11th International EAUN Meeting, 17-19 April 2010 In conjunction with the 25th Anniversary EAU Congress Programme Book European Association of Urology Nurses Contents Welcome to Barcelona 3 General Floorplan 4 General Information 7 Speaker Guidelines 12 Scientific Programme 13 EAUN Programme Overview 14 EAUN Programme Saturday, 17 April 15 EAUN Programme Sunday, 18 April 19 EAUN Programme Monday, 19 April 23 Abstracts 31 Poster Abstracts 32 Oral Abstracts 43 EAUN Membership 56 WelcomeEAUN meets to Barcelonain Barcelona byBroaden the EAU your Secretary views in General a dynamic and fascinating city Dear Colleagues, DearIt is a Friends great pleasure and Colleagues, to welcome you to Barcelona for the 11th International Meeting of the European Association of Urology Nurses (EAUN) organised with the support of the Spanish AssociationWith the renowned of Urology warm Nurses hospitality (Enfuro). and cosmopolitan ambience of Barcelona, it is with pleasure that we welcome you to our 25th Anniversary Congress. Whilst celebrating a milestoneDuring the event past year,in the the European EAUN has Association been fortunate of Urology’s to have (EAU) Mr. J.C. history, De La this Torre year’s Montero congress from alsoMadrid marks on thea crossroads board. He in has our not speciality, only gently a time guided when us wethrough are witnesses “Spanish to challenges,” fast-changing but also ensureddevelopments a very in fine medicine. collaboration with our colleagues in Spain. ThisFor thisis our year’s third programme congress in in Spain Barcelona and the significant second in emphasisBarcelona is since placed 1998, on improvingand our return to rehabilitationthis city provides in cancer us with care, the chancean area not which only is to attracting look back more to the attention. achievements For the of first European time, urologythe EAUN but will also present carefully a multi-professional assess the manifold workshop and still which unresolved will gather issues representatives that impact our from daily clinicalvarious practice.uro-oncology societies including patient advocates, a format that will ensure a broader perspective. The workshop Nursing tools for patient instruction on PCa--, made possible thanks Ourto a Scientificunique cooperation Congress withOffice various has prepared supporting a scientific companies programme who also suppliedthat aims resourceto provide packs-- clarity andpromises direction. to be With a dynamic, the results interactive of major session. research And studies do not still miss being the opportunityawaited and to technological join the final debateadvances on prodding optimising our rehabilitation treatment approaches in cancer care.into a state of renewal, we are in a period of transition. Keeping an eye to these challenges, we have invited frontline opinion leaders and Thereexperts are from several and hotoutside topics Europe on the to agenda lead and and highlight expert speakersdiscussions and on participants topics that willcover discuss the breadthwhat’s “in” of urology. in urology nursing. To name a few: Mr. H.A.M. Van Muilekom from the Netherlands will lecture on New developments in urological cancer care including the nursing aspects. As in Asprevious in previous EAUN years, meetings, we attempt we have to an bring outstanding depth and course a comprehensive from the European reach in School the plenary of Urology (ESU)sessions which through will focusthe Section on Erectile Meetings dysfunction and the. Chaired Urology by Beyond Dr. P.J. Europe,Nyirády amongstfrom Hungary, other the meetings,lectures will with take both up programmespathophysiology scheduled followed right by anon overviewthe opening of medicaland second treatment days of and the the congress.nursing aspects. TheWith ESU attendance course will figures be complemented reaching beyond by a 11,000 lecture participants on another andimportant record aspectnumbers of ED,of abstract the submissionspatient’s quality and ofexhibitors, life. Lecturer without Mr. J. doubt Albaugh, you willChicago find (US) the isnext the few former days president not only aof unique the Societylearning of experience Urologic Nurses but also and a memorableAssociates (SUNA) one as andyou initiatorre-unite ofwith the friends Global andAlliance colleagues. of Urology Nurses (GAUN). If, by chance, your society is not updated on GAUN’s activities, do not miss the chanceIn behalf to ofmeet the Jeff.EAU, Further welcome information to Barcelona, can becertainly found aat delightful www.thegaun.org. Mediterranean destination and a most fitting venue for a signpost event in the EAU’s history. A state-of-the-art lecture, The importance of patient positioning and safety on a urology OR, Bienvenidosby Mrs. K. Fitzpatrick, a Barcelona! Vice-Chair of the EAUN, will end the meeting. And stay for the award session to support your colleagues and cheer the awardees. Per-Anders Abrahamsson WeEAU Secretaryalso invite General you to the welcome reception which will be held with authentic Spanish ambience and style after the Saturday programme …and do not forget to join the new events in our programme such as the great Barcelona Urowalk and the EAUN Urology Nursing Quiz. The board looks forward to an excellent meeting. Enjoy Barcelona! Bente Thoft Jensen EAUN Chair EAUN Barcelona 2010 3 Floorplan EAURF F.M.A. To Hall 4 and 6 EAUN E Session Room Birmingham D Regional Meetings Poster E EAUN Award Winning Posters EAUN Session Room Birmingham 4 Programme Book Please visit us at EAUN Booth G02 1 Because bone complications can destroy and shorten lives, defend your patients with the essential bone-targeted therapy 2,3 Please see Data Product Sheet available at the booth. 3 Important Safety Information ZOMETA® 4 mg/5 mL concentrate for solution for infusion extraction, periodontal disease, local trauma including poorly fitting dentures). Therefore, Important note: Before prescribing, consult full prescribing information. cancer patients should maintain good oral hygiene and should have a dental examination Presentation: Zoledronic acid. Vials containing 4 mg of zoledronic acid supplied as a liquid with preventive dentistry prior to treatment with bisphosphonates. Cancer patients should concentrate for further dilution prior to use. inform their dentist while under dental treatment or if dental surgery is foreseen. A causal relationship between bisphosphonate use and ONJ has not been established. Patients treated Indications: Prevention of skeletal related events (pathological fractures, spinal compression, with Zometa (zoledronic acid) should not be treated with Aclasta. No experience in children. radiation or surgery to bone, or tumour-induced hypercalcaemia) in patients with advanced Patients who have received doses higher than those recommended should be carefully malignancies involving bone. Treatment of hypercalcaemia of malignancy (HCM). monitored, since renal function impairment (including renal failure) and serum electrolyte Prevention of fracture and bone loss in postmenopausal women with early-stage breast (including calcium, phosphorus and magnesium) abnormalities have been observed. In cancer treated with aromatase inhibitors (AIs).* the event of hypocalcaemia, calcium gluconate infusions should be administered as Dosage: Zometa must not be mixed with calcium or other divalent cation-containing infusion clinically indicated. solutions, such as Lactated Ringer’s solution, and should be administered as a single Pregnancy: See contraindications. intravenous solution in a line separate from all other drugs. For ‘prevention of skeletal related Breast-feeding: See contraindications. events in patients with advanced malignancies involving bone’, the recommended dose is 4 mg (diluted with 100 mL 0.9% w/v sodium chloride or 5% w/v glucose solution), given as Interactions: Zoledronic acid shows no appreciable binding to plasma proteins and an intravenous infusion of no less than 15 minutes every 3 to 4 weeks. Dose reduction is does not inhibit human P450 enzymes in vitro, but no formal clinical interaction studies recommended in patients with pre-existing mild to moderate renal impairment. have been performed. Caution is advised when bisphosphonates are administered with aminoglycosides, since both agents may have an additive effect, resulting in a lower For ‘treatment of HCM’, the recommended dose is 4 mg given as a single intravenous serum calcium level for longer periods than required. Caution is asked when used with infusion of no less than 15 minutes. No dose adjustment in patients with mild to moderate other potentially nephrotoxic drugs. Attention should also be paid to the possibility of renal impairment. hypomagnesaemia developing during treatment. In multiple myeloma patients, the risk of Patients without hypercalcaemia should also be administered an oral calcium supplement renal dysfunction may be increased when i.v. bisphosphonates are used in combination of 500 mg and 400 IU vitamin D daily. with thalidomide. For “Prevention of fracture and bone loss in postmenopausal women with early-stage breast Adverse reactions: Usually mild and transient and similar to those reported for other cancer treated with aromatase inhibitors (AIs)” the recommended dose is 4 mg (diluted bisphosphonates: with 100 mL 0.9% w/v sodium chloride or 5% w/v glucose solution, given as an intravenous Very common (>10%): reduction in renal calcium excretion is accompanied by a fall in serum infusion lasting no less than 15 minutes every 6 months. phosphate levels